Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

181. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis (Abstract)

The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis Heartburn and acid reflux are common medical disorders in pregnancy and can result in serious discomfort and complications. Furthermore, some pregnant women also experience more severe gastrointestinal conditions, such as Helicobacter pylori infections, peptic ulcers, and Zollinger-Ellison syndrome. To allow the use of proton pump inhibitors (PPIs) in pregnancy, the fetal safety of this drug class must be established

2009 EvidenceUpdates

182. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease Full Text available with Trip Pro

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease The proportion of patients who respond to proton pump inhibitor (PPI) therapy is about 20% lower in those with non-erosive reflux disease (NERD) than in those with erosive oesophagitis.To assess efficacy and safety of dexlansoprazole MR, a PPI using Dual Delayed Release technology, in NERD patients.In this 4-week, double-blind, placebo

2009 EvidenceUpdates Controlled trial quality: predicted high

183. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Full Text available with Trip Pro

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown.We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction (...) . The cases in our study were those readmitted with acute myocardial infarction within 90 days after discharge. We performed a secondary analysis considering events within 1 year. Event-free controls (at a ratio of 3:1) were matched to cases on age, percutaneous coronary intervention and a validated risk score. We categorized exposure to proton pump inhibitors before the index date as current (within 30 days), previous (31-90 days) or remote (91-180 days).Among 13 636 patients prescribed clopidogrel

2009 EvidenceUpdates

184. Proton Pump Inhibitor Association with Increased Risk of Clostridium difficile Associated Diarrhea

Proton Pump Inhibitor Association with Increased Risk of Clostridium difficile Associated Diarrhea "Proton Pump Inhibitor Association with Increased Risk of Clostridium d" by Kitty Earley < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Proton Pump Inhibitor use is increasing in the hospital (...) has been proposed: Proton Pump Inhibitors (PPI). Hypothesis: Hypochlorhydria from PPI is a risk factor for developing CDAD. Study Design: Systematic review of available medical literature and reviews. Methods: An extensive literature search was conducted on Medline-OVID, CINAHL (EBSCOhost), and PubMed using the search terms “proton pump inhibitor and Clostridium difficile”, “Proton Pump Inhibitors”, and “Clostridium difficile”. Relevant references were retrieved and references from the reviewed

2009 Pacific University EBM Capstone Project

185. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

186. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials

Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

187. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis

Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C CRD summary The review found a significantly lower rate of clinically important (...) bleeding when using proton pump inhibitors rather than histamine-2 receptor antagonists in the prevention of stress-related mucosal disease in critically ill patients. Rates of nosocomial pneumonia were similar. The reliability of the authors’ conclusions is unclear due to some methodological weaknesses and differences between the small number of studies. Authors' objectives To evaluate the effectiveness of proton pump inhibitors compared to histamine-2 receptor antagonists in the prevention of stress

2009 DARE.

188. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials

The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

189. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. (Abstract)

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Proton-pump inhibitors (PPIs) are often prescribed in combination with thienopyridines. Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel.In the PRINCIPLE-TIMI 44

2009 Lancet

190. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. Full Text available with Trip Pro

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. To investigate the cost effectiveness of cyclo-oxygenase-2 (COX 2) selective inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), and the addition of proton pump inhibitors to these treatments, for people with osteoarthritis.An economic evaluation using a Markov model and data from a systematic review was conducted (...) . Subgroup analyses were conducted for people at high risk of gastrointestinal or cardiovascular adverse events. Comparators Licensed COX 2 selective inhibitors (celecoxib and etoricoxib) and traditional NSAIDs (diclofenac, ibuprofen, and naproxen) for which suitable data were available were compared. Paracetamol was also included, as was the possibility of adding a proton pump inhibitor (omeprazole) to each treatment.The main outcome measure was cost effectiveness, which was based on quality adjusted

2009 BMJ

191. Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Article Text Aetiology

2009 Evidence-Based Medicine

192. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. (Abstract)

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Substantial physician workload and high costs are associated with the treatment of dyspepsia in primary health care. Despite the availability of consensus statements and guidelines, the most cost-effective empirical strategy for initial management (...) , and proton pump inhibitor (step-up; n=341), or these drugs in the reverse order (step-down; n=323), by use of a computer-generated sequence with blocks of six. Each step lasted 4 weeks and treatment only continued with the next step if symptoms persisted or relapsed within 4 weeks. Primary outcomes were symptom relief and cost-effectiveness of initial management at 6 months. Analysis was by intention to treat (ITT); the ITT population consisted of all patients with data for the primary outcome at 6

2009 Lancet Controlled trial quality: predicted high

193. Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients Full Text available with Trip Pro

Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients Radiofrequency (RF) energy delivery is an endoscopic procedure developed for the treatment of gastro-oesophageal reflux disease.To compare RF and a proton pump inhibitor strategy (PPI) in PPI-dependent patients by carrying out a prospective, randomized trial.Patients with PPI-dependent typical reflux symptoms were randomly allocated to either RF or PPI regimen alone

2008 EvidenceUpdates Controlled trial quality: uncertain

194. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: `on` or `off` proton pump inhibitor? (Abstract)

Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: `on` or `off` proton pump inhibitor? In patients with proton pump inhibitor (PPI)-resistant symptoms, ambulatory 24-h pH-impedance monitoring can be used to assess whether a relationship exists between symptoms and reflux episodes. Until now, it is unclear whether combined pH-impedance monitoring in these patients should be performed on or off PPI.Thirty patients with symptoms of heartburn, chest pain

2008 EvidenceUpdates Controlled trial quality: uncertain

195. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication Full Text available with Trip Pro

Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication The evidence on whether high-dose proton pump inhibitors (PPIs) increase cure rates of Helicobacter pylori treatment has not been previously assessed.To evaluate the evidence on the usefulness of high-dose PPI in standard triple therapy by performing a systematic review and a meta-analysis.A systematic search was performed in multiple databases and in the abstracts submitted

2008 EvidenceUpdates

196. Proton-pump inhibitor use and the risk for community-acquired pneumonia. (Abstract)

Proton-pump inhibitor use and the risk for community-acquired pneumonia. Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP).To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom.Nested case-control study.The General Practice Research Database (1987 to 2002) in the United Kingdom.Patients age 18 years or older with at least 6 months of initial pneumonia-free follow-up (...) matched case-control analysis, which included the 3 strongest confounders as additional matching factors, yielded similar results as the primary analysis (adjusted OR, 0.96 [CI, 0.91 to 1.02]).Adherence to PPI prescription was assumed to be 100%. No radiographic evidence was available to corroborate a diagnosis of CAP.Proton-pump inhibitor therapy started within the past 30 days was associated with an increased risk for CAP, whereas longer-term current use was not.

2008 Annals of Internal Medicine

197. Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia

Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) inhibitors improve global symptoms in non-ulcer dyspepsia Article Text Therapeutics Review: prokinetics, histamine H 2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse

2008 Evidence-Based Medicine

198. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention

Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Saini S D, Schoenfeld P, Fendrick A M, Scheiman J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of long-term therapy with low-dose aspirin (ASA) plus proton-pump inhibitor (PPI) co-therapy, compared with ASA alone, for the prevention of upper gastrointestinal bleeding

2008 NHS Economic Evaluation Database.

199. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial

Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

200. Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants

Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Gieruszczak-Bialek D, Skorka A, Szajewska H CRD summary The review evaluated the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease in infants (...) and found limited evidence that omeprazole significantly reduced reflux. The review was generally well conducted. The authors’ conclusion that there was insufficient evidence for the use of proton pump inhibitors for treatment of gastro-oesophageal reflux disease in infants seems reliable. Authors' objectives To evaluate the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease (GORD) in infants. Searching MEDLINE (1966-2007), EMBASE (1980-2007

2008 DARE.